Wednesday, October 03 - Sunday, October 07
San Francisco, CA
May 31, 2018
VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be featured in the New Agents Discovery Summary Session: Early New Antimicrobial Agents; Emerging Tech Talks; and five poster presentations on June 8-9, 2018 in Atlanta, GA.
May 17, 2018
President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of VenatoRx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.
April 19, 2018
The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Drs. Burns, Xerri and Pevear were selected as finalists by a panel of independent judges. Award winners will be announced at a special gala event on June 14, 2018 at the Kimmel Center for the Performing Arts.
April 12, 2018
Fourteen poster presentations, including four oral sessions, will feature VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, VenatoRx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.
March 19, 2018
President and CEO, Christopher J. Burns, Ph.D., will present the Company's lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium at the American Chemical Society (ACS) National Meeting on Wednesday, March 21, 2018 at 3:15pm CT. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”
January 04, 2018
The funding will support discovery and preclinical development of a novel, first-in-class antibiotic for biodefense applications. The project derives from the company’s proprietary platform of non-beta-lactam penicillin binding protein inhibitors (PBPis).
January 03, 2018
The FDA granted VenatoRx's lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, both the Qualified Infectious Disease Product (QIDP) and Fast Track designations. The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
July 27, 2017
The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents beta-lactam antibiotic resistance, but with the same safe and effective mechanism of action of beta-lactams.